SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Transfusion Reduction

SOLIRIS significantly reduces or eliminates the need for transfusions regardless of pretreatment transfusion requirements

The majority of SOLIRIS patients became transfusion independent

Transfusion Reduction

  • Transfusion independence was achieved in 51% of SOLIRIS® (eculizumab)-treated patients
     
  • SOLIRIS-treated patients still requiring transfusions achieved a 44% reduction in their overall transfusion requirements
     
  • All placebo patients required at least 1 transfusion by week 142
     

SOLIRIS reduced transfusions for patients with mild, moderate, and high pretreatment transfusion needs.

Transfusion Reduction

A majority of SOLIRIS-treated patients became transfusion independent regardless of pretreatment transfusion requirements.1,2

  • The mean number of units transfused was 73% lower in SOLIRIS vs. placebo-treated patients2

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Next: SOLIRIS and Fatigue Reduction

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References:
1. Data on File. Alexion Pharmaceuticals, Inc.
2. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.